ICRP 123: Cl35 - dawki narządowe i współczynniki jakości
Źródło: ICRP Publication 123, Assessment of Radiation Exposure of Astronauts in Space, supplementary data, Annals of the ICRP 42(4), 2013, strony PDF: arkusz Cl35. Podpis w źródle: Supplementary data workbook P 123 JAICRP 42(4) DB of heavy ion.xls, sheet Cl35
Znormalizowana macierz danych ICRP 123 dla cząstki Cl35: energia, narząd lub wielkość efektywna, płeć fantomu, typ wielkości, jednostka i wartość. Dane obejmują współczynniki konwersji fluencji cząstek na dawkę pochłoniętą oraz średnie współczynniki jakości w geometrii izotropowej.
Źródłowe arkusze miały układ szeroki z wielopoziomowymi nagłówkami; import zapisano w układzie długim, aby można było filtrować po energii, narządzie, płci i typie wielkości.
Kolumny SwTDT/F, DT/F, QICRP60 i QNASA zachowują nazwy źródłowe z arkusza. Jednostka pGy cm2 lub pSv cm2 jest podana w kolumnie jednostka wartości.
Pokazano 4392 z 4392 wierszy.
| Cząstka | Symbol | Z | A | Energia | Jednostka energii | Narząd/tkanka albo wielkość | Płeć/fantom | Wielkość źródłowa | Opis wielkości | Jednostka wartości | Wartość |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 61.7 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 55.8 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 67.7 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5580 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6770 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 1 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 123 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 111 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 135 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 11100 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 13500 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 2 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 185 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 167 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 203 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 16700 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 20300 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 3 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 307 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 278 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 337 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 27800 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 33700 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 5 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 719 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 693 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 745 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6.97 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2.1 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 572 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 630 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 815 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 22.6 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 4.78 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6.44 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55100 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66800 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 62.9 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 8.42 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 733 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 105 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 34.9 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 49.5 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 3.64 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 10 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 1030 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 991 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 1060 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 9.58 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1.2 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 3.29 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1.2 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1020 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.4 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1090 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.118 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.116 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.121 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.128 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.125 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.6 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.124 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.4 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1130 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.121 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.127 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.4 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.316 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.5 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.174 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 32.1 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 7.06 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.152 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.161 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 11.5 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.211 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 76600 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 92700 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 96.7 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 11 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1130 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 136 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.116 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.11 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.108 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54.7 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.158 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 73 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5.86 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.116 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.158 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.0984 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.2 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.114 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.4 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.113 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.138 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.135 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.6 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.232 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2.92 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2.92 |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 14 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 1510 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 1470 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 1540 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 15.9 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5.58 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2040 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1930 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.469 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.471 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.465 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.482 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.373 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.486 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1620 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.274 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.431 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.457 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.333 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.429 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.542 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.739 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.411 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.608 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 50.2 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 11.8 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.569 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.602 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 32.3 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.09 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 108000 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 130000 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 151 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 23.6 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.411 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.433 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1760 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 288 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.472 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.377 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.419 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.454 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.404 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.45 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 94.2 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.684 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 109 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 9.3 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.489 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 4.39 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.352 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.424 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.377 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.48 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.428 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.423 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.383 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.448 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0.75 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 0 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 13.9 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 13.9 |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 2390 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.4 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 2400 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 2390 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 28.1 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.2 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1.9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 10.4 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 4700 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 4190 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.64 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.6 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.59 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.5 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.59 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.65 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.48 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.7 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.5 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2850 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.4 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.62 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.45 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.56 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.49 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.47 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 3.1 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2.95 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.58 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.6 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2.78 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 86.7 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.2 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 21.6 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2.01 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2.27 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 85.3 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5.21 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 157000 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 187000 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 243 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.4 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 38.1 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.13 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.4 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.2 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2750 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 448 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.32 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.24 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.43 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.54 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.34 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.37 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 205 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 3.33 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 187 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 18.2 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2.29 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 13.1 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.32 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.3 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.2 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.14 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.29 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.45 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.48 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.45 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1.54 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2.59 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2.57 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63.2 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63.2 |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 30 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 4940 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 5350 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 4530 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 75 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 31.7 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 21000 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 18200 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 8.2 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 8.68 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 7.76 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 8.64 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6.63 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 9.37 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6480 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 4.33 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6.88 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 8.27 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6.87 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6.73 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 21.5 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 27 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6.49 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 16.9 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 209 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 62.5 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 12.7 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 15.2 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 933 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 39.5 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 222000 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 232000 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 583 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 96 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5.95 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5.61 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6180 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1010 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5.35 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5.01 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6.29 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 7.02 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5.49 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5.77 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 853 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 23.7 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 465 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64.3 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 13.5 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 90.4 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 4.8 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5.63 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5.07 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5.01 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6.32 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6.57 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6.19 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 7.83 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 17.9 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 15.7 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 34700 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 34700 |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 9810 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 11900 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 7750 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 248 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 182 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.1 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 70000 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 47900 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 46.6 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 42.4 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 39 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 45.8 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.3 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 30.9 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 45.5 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.3 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 15500 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 14.9 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 31.3 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 40.6 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 27.7 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 30.8 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 98.7 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 104 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 24.6 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71.9 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.3 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 664 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 305 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69.5 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 86.1 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 9850 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1110 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 187000 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.3 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 18.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 190000 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.6 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 18.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1680 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.6 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 338 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.3 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 20.5 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 17.5 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.6 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 14400 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2610 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 22.1 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 18.9 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 28.2 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 34.6 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.6 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 22.4 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 24.5 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5130 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 178 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2010 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.8 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 526 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.1 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 79.4 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 816 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.1 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 14.1 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 20.9 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 15.6 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 17.8 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 27.7 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 30 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 27.7 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.7 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 38 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61.8 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63.9 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 203000 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 203000 |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 75 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 14900 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 18700 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 11100 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 918 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1290 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 115000 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 15.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74800 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 15.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 182 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 135 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 132 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 156 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 100 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 142 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 28600 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 15.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 49.2 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 96.4 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 129 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 87.8 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 103 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 317 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 353 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84.7 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 813 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2600 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2730 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 211 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 249 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 32300 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 11200 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 157000 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 22.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 156000 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 18.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 23.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 3880 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1460 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67.9 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64.8 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 28300 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 14.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 9330 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69.6 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63.9 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 90.8 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 112 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 70.7 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82.2 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 11500 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1920 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 7940 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2570 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1340 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 4060 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 40.9 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71.7 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 47.2 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53.7 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 88.4 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 101 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 100 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 134 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 843 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 437 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 178000 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 178000 |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16 | |
| Cl35 | Cl-35 | 17 | 35 | 100 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.5 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 24300 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.8 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.8 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 29100 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 19600 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.1 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 11200 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.6 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 10500 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 158000 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 22 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 109000 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1110 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1120 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 794 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 824 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 458 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 916 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53700 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.8 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 318 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 554 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1060 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 870 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.6 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 663 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 17800 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 26300 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13.9 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 397 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 22400 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.9 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 15.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 25000 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 15.9 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 21900 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 3040 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6460 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.5 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 76000 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.9 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.1 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 45500 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.9 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 123000 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 26.6 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 124000 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.5 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 26.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 10300 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 18.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 7170 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 349 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.1 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 366 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53900 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.5 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 30900 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 18.1 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 364 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 380 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 446 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 559 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 393 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 442 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 23600 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.1 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 18000 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 31000 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.8 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 16300 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 15.5 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 9800 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 16400 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.8 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.5 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 274 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.4 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 435 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.5 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.1 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 298 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.5 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 323 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.5 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 466 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 473 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 478 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.5 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.1 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 592 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 12200 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 14.7 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 8020 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13.5 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 132000 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 25.6 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 132000 |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 150 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 25.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 32200 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 18.5 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.8 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 35100 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.5 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 29300 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 20100 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 20600 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 142000 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 25.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 113000 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 24.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 10500 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 11500 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 15.3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6520 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 7820 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2540 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 13900 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71900 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 18.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 22.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 978 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.8 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6640 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 9710 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 14.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5810 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 14.3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5110 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56000 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65500 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1220 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 4.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 37200 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.8 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 46000 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 43700 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.7 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 24800 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 37400 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.8 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 89800 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 23.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 73800 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 109000 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 26.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 110000 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 26.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 17400 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 15200 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.8 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1040 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1020 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68800 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 23.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 41700 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 18.3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 22.7 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2120 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1140 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 3330 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5310 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.5 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1130 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1190 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 29900 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 22.7 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 28000 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.5 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54500 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 41100 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 18400 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 32400 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 848 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.7 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1130 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 880 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.7 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 1070 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 2.3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 3750 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 3680 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 2110 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 5560 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 39900 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.6 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 18.4 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 34100 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.3 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.9 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 114000 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 24.2 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 114000 |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.1 | |
| Cl35 | Cl-35 | 17 | 35 | 200 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 24.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 55600 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.7 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 56100 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 55100 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.8 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 42200 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 44800 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 117000 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 25.9 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 24.8 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 103000 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 24.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 24.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 49600 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 18.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.7 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53000 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 18.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.7 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 49200 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67800 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.9 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 37100 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 51700 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 18.8 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.9 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 72000 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 24.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 3850 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 34500 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 46900 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 18.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 22000 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 18 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 28300 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 76300 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 24.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66900 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 24.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 28900 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.7 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 48200 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 22.7 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 83400 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 23.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81900 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 22.9 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 83800 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 22.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 95400 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 22.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 93300 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 24.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 87400 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 23.9 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 101000 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 26 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 23.8 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 103000 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 25.9 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 23.8 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 40600 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 42400 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 18.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 21200 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 12900 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81300 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 23.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74100 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 16800 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 18.7 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 9630 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 31100 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 41600 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 23600 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.8 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 24000 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.7 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 45200 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 22.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 47600 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 22 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84700 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 23.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 80100 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 23 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 79900 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 18.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 88300 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 22.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 3120 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 17800 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 15.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 3780 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 6310 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 32100 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 37000 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 40500 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.4 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55400 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.9 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63900 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.2 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 23.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56100 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.1 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 23.6 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 112000 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 25.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 24 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 112000 |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 25.3 | |
| Cl35 | Cl-35 | 17 | 35 | 300 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 24 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 86800 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 18.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 84100 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 18.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 89500 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 18.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 83300 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 89500 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.6 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 90000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.1 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 89800 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 78000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 80800 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.6 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 95100 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.4 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.1 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 101000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 76000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 83800 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 78300 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.3 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.3 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84200 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.4 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 78900 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.6 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84300 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 86600 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.4 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 104000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.1 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.3 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 85700 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 99700 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.6 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74600 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 97100 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 100000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 120000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 117000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.6 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.4 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 107000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.6 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 102000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 98000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.1 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 101000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.1 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 19.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82500 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.4 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 89100 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 89000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.4 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 109000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.1 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 95800 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.4 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71100 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 85700 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.4 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 86200 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 93900 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 73700 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.6 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81900 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.1 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82100 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.3 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 88800 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 92600 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 95300 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 108000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.4 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 104000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 23.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 75400 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 18.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82400 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.1 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71100 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.5 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 77900 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.1 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74400 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 77800 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.1 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 77300 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 21.4 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.8 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 87900 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.3 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.9 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 86600 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.4 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20.1 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 97800 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 21.2 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 102000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 102000 |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 22.7 | |
| Cl35 | Cl-35 | 17 | 35 | 500 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 20 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 81000 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 15.4 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 79900 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 15.4 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 82100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 15.4 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 77400 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 79600 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 91500 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.4 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 94600 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 72200 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 76100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84400 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.6 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 73700 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 78100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.6 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 87600 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.6 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71300 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.3 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 76700 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81200 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 75600 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82300 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 87900 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.6 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 89600 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 73500 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.4 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 83300 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 85300 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.4 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 88800 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 86700 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 89800 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.6 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 89800 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.2 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.3 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 91300 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.4 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 78400 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82600 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 73800 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.3 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82900 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.2 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 83100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 93300 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74400 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 80400 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 77000 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.2 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 79800 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 73700 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.2 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 79100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 77700 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.6 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 80100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81800 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 83100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.9 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82900 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 95300 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.6 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74900 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 78100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.6 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82600 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 83900 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17.4 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 72500 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.3 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 17 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 76400 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.5 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 77500 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.4 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 80100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 19.8 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 87100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.4 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.7 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81000 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.6 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 94100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.1 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 94100 |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 20.3 | |
| Cl35 | Cl-35 | 17 | 35 | 700 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 16.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 65000 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.9 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.2 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 64500 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.9 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.2 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 65500 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.2 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 62300 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.6 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.7 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 62900 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.7 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.7 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 78600 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 75500 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 62100 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.6 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61000 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64600 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.9 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67300 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58900 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.3 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63200 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.7 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63900 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.9 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59500 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.2 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.6 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61000 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 62700 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59300 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 60800 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.2 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66700 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74200 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56600 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67700 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.7 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68900 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68400 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 73000 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.6 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74500 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74400 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 73900 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.7 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 77800 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 78800 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 13 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 62400 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.6 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63300 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.6 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61500 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54200 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74400 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.9 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69100 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58400 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.2 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65200 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.3 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 60500 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.2 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 62700 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 60000 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.2 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59500 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64200 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64200 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69100 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67700 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.3 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68300 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71700 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55200 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61600 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53500 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.6 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.4 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58300 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59900 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59200 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.3 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63200 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 62600 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.5 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63000 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.2 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66400 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.7 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 77900 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.3 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 77900 |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 17.3 | |
| Cl35 | Cl-35 | 17 | 35 | 1000 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 55100 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 55200 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 55000 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52000 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53400 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68300 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66100 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 50900 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 51000 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54900 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57100 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.6 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52600 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52000 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59400 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 47700 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 51000 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53400 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 50700 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52000 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56700 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.6 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.6 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61600 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 47000 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 50700 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58900 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59300 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58700 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63100 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61200 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 62400 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.3 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69200 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.3 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69400 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52900 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53400 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 48100 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 49600 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63600 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59800 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 48100 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.6 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 50300 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 51900 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52700 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52100 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 49200 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52900 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54400 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58700 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57800 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59200 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61200 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 47000 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 49600 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 47200 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 48800 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 48400 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 49600 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 50600 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54300 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 60100 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.4 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56800 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.2 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71800 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71800 |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.7 | |
| Cl35 | Cl-35 | 17 | 35 | 2000 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 56300 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 56200 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 56300 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53100 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54300 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 73300 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67000 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.4 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 50300 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53800 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56200 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58200 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.2 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 51300 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53100 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57400 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 49300 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52600 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54100 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52100 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56800 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57900 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57800 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 50600 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.4 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53000 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59800 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59900 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61900 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65600 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67200 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 60900 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.2 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69900 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 70600 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.4 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53500 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54600 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 50800 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54000 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64400 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58900 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 49300 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 51400 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52500 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54500 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 48400 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.4 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52400 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54000 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55000 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.4 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59900 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59400 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61700 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61700 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 45000 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 50400 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 50200 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 50800 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.4 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 49400 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 51600 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53300 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 51600 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57000 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58100 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 70200 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.6 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 70200 |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.5 | |
| Cl35 | Cl-35 | 17 | 35 | 3000 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 8.6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 60400 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.1 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 59500 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 61400 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.1 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57300 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59100 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66700 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.2 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68100 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57800 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 60100 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 60800 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.1 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63600 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53300 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 60200 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61600 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 51800 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56700 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59900 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 61800 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65500 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63700 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67100 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54100 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58300 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64000 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64500 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65900 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65300 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.5 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66000 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68500 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 72700 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.5 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74300 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57500 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59500 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57200 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 53500 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66700 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.9 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 70000 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.9 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54800 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54800 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56800 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58200 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55300 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56900 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58600 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 60400 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63800 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.9 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64200 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.1 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65300 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69000 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 51900 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55000 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 51400 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55900 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54500 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56500 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55000 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55400 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55800 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63600 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69700 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69700 |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.4 | |
| Cl35 | Cl-35 | 17 | 35 | 5000 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 61700 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 61600 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 61700 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 60200 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58800 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 72300 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 70700 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.9 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56900 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59600 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65000 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64700 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55200 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58400 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63500 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57300 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58300 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59000 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57200 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59200 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 62800 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64100 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.4 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55900 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 62400 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65300 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63900 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69000 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64700 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69900 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63300 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 75500 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 75200 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59900 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 60100 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57500 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58300 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69000 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68700 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55700 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58600 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 60500 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58600 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 55300 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57300 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63300 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58400 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65500 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.4 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63700 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67000 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66600 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 54800 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 56400 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.9 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 51000 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 52800 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57200 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 57000 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.2 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 58600 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.5 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 59700 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63700 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65400 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69600 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69600 |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15 | |
| Cl35 | Cl-35 | 17 | 35 | 10000 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 69900 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 69500 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 70400 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66600 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67300 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 2.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 85300 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81900 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63600 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69500 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68200 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71500 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65800 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67000 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71700 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67800 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68500 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63700 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65200 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68100 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65500 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 72300 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64300 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66800 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 72600 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69900 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 75900 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71900 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 73800 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 70200 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82100 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81500 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68500 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69200 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 63400 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64200 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 79700 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74000 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71000 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66400 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66700 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68200 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 66400 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65000 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65100 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 69800 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 72800 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71900 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 74000 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 75900 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65400 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64400 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65800 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 67000 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 64000 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 68100 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 65800 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.6 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 73000 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71000 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.3 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 71700 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.4 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.2 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 85200 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 85200 |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.8 | |
| Cl35 | Cl-35 | 17 | 35 | 20000 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 85500 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 87700 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 83300 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84700 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82200 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 94700 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 89500 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 87900 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82300 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 87800 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82700 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 86900 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 83000 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 95300 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 78500 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 83900 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 79600 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 85200 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 79300 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81900 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84700 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84500 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84600 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 86600 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84800 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81400 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 90900 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 90200 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 87200 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 94500 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 94700 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 16.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 6.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84400 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82700 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84500 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 88600 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82800 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81400 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81200 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82400 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 84500 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 80400 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 88400 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 80900 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 85600 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 80500 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 87900 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 86100 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 88200 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 79800 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 80000 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 81600 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.3 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 85800 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82000 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 79500 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.6 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 82500 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 80800 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 86300 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 88300 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 83200 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 80100 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 80100 |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.1 | |
| Cl35 | Cl-35 | 17 | 35 | 50000 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Effective dose equivalent | Sex-averaged | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 103000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Effective dose equivalent | Sex-averaged | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Effective dose equivalent | Sex-averaged | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Effective dose equivalent | Male | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 105000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Effective dose equivalent | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Effective dose equivalent | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Effective dose equivalent | Female | SwTDT/F | wazony wspolczynnik dawki z naglowka zrodla SwTDT/F | pGy cm2 | 101000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Effective dose equivalent | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Effective dose equivalent | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Red bone marrow | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 107000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Red bone marrow | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Red bone marrow | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Red bone marrow | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 98600 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Red bone marrow | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Red bone marrow | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 1.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Breast | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 115000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Breast | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Breast | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Breast | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 105000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Breast | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Breast | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Colon | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 103000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Colon | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Colon | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Colon | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 108000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Colon | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Colon | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Lungs | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 106000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Lungs | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Lungs | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Lungs | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 96700 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Lungs | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Lungs | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Stomach wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 103000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Stomach wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Stomach wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Stomach wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 101000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Stomach wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Stomach wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Gonads | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 103000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Gonads | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Gonads | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Gonads | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 101000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Gonads | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Gonads | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Liver | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 105000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Liver | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Liver | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Liver | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 101000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Liver | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Liver | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Oesophagus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 101000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Oesophagus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Oesophagus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Oesophagus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 98000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Oesophagus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Oesophagus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Thyroid | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 97300 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Thyroid | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Thyroid | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Thyroid | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 100000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Thyroid | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Thyroid | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Urinary bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 107000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Urinary bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Urinary bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Urinary bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 104000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Urinary bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Urinary bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Endosteum (Bone surface) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 102000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Endosteum (Bone surface) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Endosteum (Bone surface) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Endosteum (Bone surface) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 100000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Endosteum (Bone surface) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Endosteum (Bone surface) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Brain | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 96500 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Brain | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Brain | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Brain | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 97800 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Brain | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Brain | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Salivary glands | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 102000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Salivary glands | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Salivary glands | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Salivary glands | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 99300 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Salivary glands | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 14.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Salivary glands | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Skin | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 109000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Skin | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Skin | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Skin | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 107000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Skin | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Skin | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Remainder tissues | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 104000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Remainder tissues | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Remainder tissues | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Remainder tissues | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 101000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Remainder tissues | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Remainder tissues | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Adrenals | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 107000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Adrenals | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Adrenals | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Adrenals | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 97100 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Adrenals | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Adrenals | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Extrathoracic (ET) region | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 104000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Extrathoracic (ET) region | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Extrathoracic (ET) region | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Extrathoracic (ET) region | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 104000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Extrathoracic (ET) region | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Extrathoracic (ET) region | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Gall bladder wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 105000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Gall bladder wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Gall bladder wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Gall bladder wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 95500 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Gall bladder wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Gall bladder wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Heart wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 101000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Heart wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Heart wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Heart wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 99100 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Heart wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Heart wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Kidneys | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 105000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Kidneys | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Kidneys | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Kidneys | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 103000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Kidneys | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Kidneys | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Lymphatic nodes | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 102000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Lymphatic nodes | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Lymphatic nodes | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Lymphatic nodes | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 99900 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Lymphatic nodes | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Lymphatic nodes | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Muscle | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 105000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Muscle | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Muscle | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Muscle | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 102000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Muscle | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Muscle | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.7 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Oral mucosa | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 101000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Oral mucosa | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 13.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Oral mucosa | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Oral mucosa | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 97100 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Oral mucosa | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Oral mucosa | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Pancreas | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 104000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Pancreas | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Pancreas | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Pancreas | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 102000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Pancreas | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 9.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Pancreas | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Prostate (male) / Uterus (female) | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 109000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Prostate (male) / Uterus (female) | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 7.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Prostate (male) / Uterus (female) | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Prostate (male) / Uterus (female) | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 101000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Prostate (male) / Uterus (female) | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.1 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Prostate (male) / Uterus (female) | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Small intestine wall | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 103000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Small intestine wall | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.6 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Small intestine wall | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.8 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Small intestine wall | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 102000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Small intestine wall | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Small intestine wall | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Spleen | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 103000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Spleen | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 8.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Spleen | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 3.9 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Spleen | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 103000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Spleen | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 10.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Spleen | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Thymus | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 104000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Thymus | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 12.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Thymus | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.4 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Thymus | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 102000 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Thymus | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 11 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Thymus | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 4.5 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Eye lens | Male | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 97500 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Eye lens | Male | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Eye lens | Male | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Eye lens | Female | DT/F | wspolczynnik dawki pochlonietej DT/F | pGy cm2 | 97500 |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Eye lens | Female | QICRP60 | sredni wspolczynnik jakosci Q wedlug ICRP 60 | 15.2 | |
| Cl35 | Cl-35 | 17 | 35 | 100000 | MeV/u | Eye lens | Female | QNASA | sredni wspolczynnik jakosci Q wedlug koncepcji NASA | 5.3 |